STOCK TITAN

Apellis Pharmace - APLS STOCK NEWS

Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.

Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.

Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.

Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.

Rhea-AI Summary
Apellis Pharmaceuticals to discuss Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences earnings
-
Rhea-AI Summary
Apellis Pharmaceuticals announces positive 24-month results for SYFOVRE in treating geographic atrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
Positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences clinical trial
Rhea-AI Summary
Apellis Pharmaceuticals grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals provides update on launch of SYFOVRE for geographic atrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals receives FDA approval for the EMPAVELI Injector, a compact on-body device for self-administration of EMPAVELI in PNH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
Rhea-AI Summary
Apellis Pharmaceuticals announces permanent J-code for SYFOVRE, the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
Rhea-AI Summary
Apellis Pharmaceuticals to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
Apellis Pharmace

Nasdaq:APLS

APLS Rankings

APLS Stock Data

2.28B
107.71M
13.86%
103.5%
16.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM